|
|
Blood, 15 July 2008, Vol. 112, No. 2, pp. 362-373.
Prepublished online as a Blood First Edition Paper on March 19, 2008; DOI 10.1182/blood-2007-11-120998.
Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
Tumor-specific Th17-polarized cells eradicate large established melanoma
Pawel Muranski1,*,
Andrea Boni1,*,
Paul A. Antony1,*,
Lydie Cassard1,
Kari R. Irvine1,
Andrew Kaiser1,
Chrystal M. Paulos1,
Douglas C. Palmer1,
Christopher E. Touloukian1,
Krzysztof Ptak2,
Luca Gattinoni1,
Claudia Wrzesinski1,
Christian S. Hinrichs1,
Keith W. Kerstann1,
Lionel Feigenbaum3,
Chi-Chao Chan4, and
Nicholas P. Restifo1
1 Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health, Mark O. Hatfield Clinical Research Center, Bethesda, MD;
2 National Institute of Neurological Disorders and Stroke, Bethesda, MD;
3 Science Applications International Corporation (SAIC), NCI, Frederick, MD; and
4 Laboratory of Immunology, National Eye Institute, Bethesda, MD
CD4+ T cells can differentiate into multiple effector subsets, but the potential roles of these subsets in anti-tumor immunity have not been fully explored. Seeking to study the impact of CD4+ T cell polarization on tumor rejection in a model mimicking human disease, we generated a new MHC class II-restricted, T-cell receptor (TCR) transgenic mouse model in which CD4+ T cells recognize a novel epitope in tyrosinase-related protein 1 (TRP-1), an antigen expressed by normal melanocytes and B16 murine melanoma. Cells could be robustly polarized into Th0, Th1, and Th17 subtypes in vitro, as evidenced by cytokine, chemokine, and adhesion molecule profiles and by surface markers, suggesting the potential for differential effector function in vivo. Contrary to the current view that Th1 cells are most important in tumor rejection, we found that Th17-polarized cells better mediated destruction of advanced B16 melanoma. Their therapeutic effect was critically dependent on interferon- (IFN- ) production, whereas depletion of interleukin (IL)–17A and IL-23 had little impact. Taken together, these data indicate that the appropriate in vitro polarization of effector CD4+ T cells is decisive for successful tumor eradication. This principle should be considered in designing clinical trials involving adoptive transfer–based immunotherapy of human malignancies.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Article in Blood Online:
-
Th17 and cancer: friends or foes?
- Vincenzo Bronte
Blood 2008 112: 214.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
Z.-Z. Yang, A. J. Novak, S. C. Ziesmer, T. E. Witzig, and S. M. Ansell
Malignant B Cells Skew the Balance of Regulatory T Cells and TH17 Cells in B-Cell Non-Hodgkin's Lymphoma
Cancer Res.,
July 1, 2009;
69(13):
5522 - 5530.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. K. McKinstry, T. M. Strutt, A. Buck, J. D. Curtis, J. P. Dibble, G. Huston, M. Tighe, H. Hamada, S. Sell, R. W. Dutton, et al.
IL-10 Deficiency Unleashes an Influenza-Specific Th17 Response and Enhances Survival against High-Dose Challenge
J. Immunol.,
June 15, 2009;
182(12):
7353 - 7363.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. D. Sharma, D.-Y. Hou, Y. Liu, P. A. Koni, R. Metz, P. Chandler, A. L. Mellor, Y. He, and D. H. Munn
Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes
Blood,
June 11, 2009;
113(24):
6102 - 6111.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Phan and M. L. Disis
Tumor-Specific Th1 Lymphocytes: Modulation of the Tumor Microenvironment to Enhance Cross-Priming
Am. Assoc. Cancer Res. Educ. Book,
April 18, 2009;
2009(1):
199 - 202.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. M. Long, H. W.M. van Laarhoven, J. W.M. Bulte, and H. I. Levitsky
Magnetovaccination as a Novel Method to Assess and Quantify Dendritic Cell Tumor Antigen Capture and Delivery to Lymph Nodes
Cancer Res.,
April 1, 2009;
69(7):
3180 - 3187.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Y. Gerner and M. F. Mescher
Antigen Processing and MHC-II Presentation by Dermal and Tumor-Infiltrating Dendritic Cells
J. Immunol.,
March 1, 2009;
182(5):
2726 - 2737.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. H. Schreiber, V. V. Deyev, J. D. Rosenblatt, and E. R. Podack
Tumor-Induced Suppression of CTL Expansion and Subjugation by gp96-Ig Vaccination
Cancer Res.,
March 1, 2009;
69(5):
2026 - 2033.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. W. Kappel, G. L. Goldberg, C. G. King, D. Y. Suh, O. M. Smith, C. Ligh, A. M. Holland, J. Grubin, N. M. Mark, C. Liu, et al.
IL-17 contributes to CD4-mediated graft-versus-host disease
Blood,
January 22, 2009;
113(4):
945 - 952.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Yee
Adoptive T Cell Therapy: Stratagems and Spoils
ASCO Educational Book,
January 1, 2009;
2009(1):
511 - 515.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Boni, P. Muranski, L. Cassard, C. Wrzesinski, C. M. Paulos, D. C. Palmer, L. Gattinoni, C. S. Hinrichs, C.-C. Chan, S. A. Rosenberg, et al.
Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers
Blood,
December 1, 2008;
112(12):
4746 - 4754.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|